Drotaverine Hydrochloride is effectively used in the treatment of management of spasticity, indicated in muscle pain as muscle relaxant. Drotaverine Hydrochloride approximately 95% bounds to plasma proteins and is metabolized by liver. In the present investigation, efforts were put to develop a sustained release floating matrix tablets of Drotaverine Hydrochloride. Gastro retentative dosage form will also greatly improve the pharmacotherapy of the stomach itself through local drug release leading to high drug concentrations at the gastric mucosa, which are sustained over a long period of time. Floating matrix tablets were prepared by direct compression method using sodium bicarbonate and citric acid as gas forming agents. HPMC K100M and Ethyl cellulose were used in the formula to retard drug release. Floating matrix tablets were evaluated for different quality attributes. In vitro drug release showed that polymer percentage is enough to extend the release of the drug for at least 12 hr. The dissolution curve shows that formulation FT-6 shows maximum drug release 79.37% at the end of 12 hours while FT-7 shows least 46.33 %.
展开▼
